Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
0.229
-0.027 (-10.44%)
At close: Aug 30, 2024, 4:00 PM
0.215
-0.014 (-6.11%)
After-hours: Aug 30, 2024, 7:59 PM EDT
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $2.21M in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $12.46M. In the year 2023, Tonix Pharmaceuticals Holding had annual revenue of $7.77M.
Revenue (ttm)
$12.46M
Revenue Growth
n/a
P/S Ratio
0.04
Revenue / Employee
$120,951
Employees
103
Market Cap
5.04M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
iCoreConnect | 10.27M |
MSP Recovery | 7.51M |
Azitra | 408.20K |
Silo Pharma | 72.10K |
Ainos | 65.12K |
TNXP News
- 2 days ago - Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) - GlobeNewsWire
- 5 days ago - Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine - Benzinga
- 5 days ago - Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801 - GlobeNewsWire
- 8 days ago - Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency - Accesswire
- 12 days ago - Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 15 days ago - Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency - GlobeNewsWire
- 4 weeks ago - FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate - Accesswire
- 4 weeks ago - Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™ - GlobeNewsWire